Yoel Brito, MD
Pulmonary Disease · Miami, FLNPI 1437448271
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 70.7% of it on its own, with 33 other manufacturers making up the rest. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 663 payments — averaging $71.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$33K
- GSK$4K
- Chiesi USA, Inc.$2K
- Boehringer Ingelheim$1K
- Sanofi$885
- Baxter Healthcare$772
- plus $5K from 28 others
Across 222 payments — averaging $3400.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$671K
- Incyte Corporation$84K
What the payments were for
- Speaking & faculty fees$27,54258%
- Travel & lodging$3,2987%
- Food & beverage$16,28834%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 181 | $33,377 |
| GSK | 183 | $3,627 |
| Chiesi USA, Inc. | 2 | $2,316 |
| Boehringer Ingelheim | 61 | $1,380 |
| Sanofi | 32 | $885 |
| Baxter Healthcare | 30 | $772 |
| Mylan Specialty L.p. | 33 | $755 |
| Amgen | 20 | $559 |
| Verona Pharma, Inc. | 19 | $509 |
| Insmed, Inc. | 23 | $485 |
| Inogen, Inc. | 8 | $419 |
| Philips North America LLC | 11 | $397 |
| Advanced Respiratory, Inc | 14 | $355 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $268 |
| Inspire Medical Systems, Inc. | 3 | $228 |
| Regeneron Healthcare Solutions, Inc. | 4 | $114 |
| Viatris Specialty LLC | 3 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Sunovion Pharmaceuticals Inc. | 3 | $78 |
| Grifols USA, LLC | 3 | $74 |
| Lilly USA, LLC | 3 | $57 |
| Merck | 2 | $52 |
| Circassia Inc. | 3 | $48 |
| United Therapeutics Corporation | 2 | $47 |
| Azurity Pharmaceuticals, Inc. | 2 | $39 |
| Pulmonx Corporation | 1 | $34 |
| Fisher & Paykel Healthcare Inc | 1 | $33 |
| Novartis | 1 | $30 |
| Pfizer | 1 | $26 |
| UCB, Inc. | 1 | $21 |
| Electromed, Inc. | 1 | $19 |
| Resmed Corp | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$23,343
- TEZSPIRE$6,469
- INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH$188
- Inspire$140
- NUCALA$110
- Reusable Vest$100
How this compares
$47,225 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,377 | $952,358 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 1,007 | $685,752 |
| OfevNintedanib Esylate | 37 | $470,361 |
| NucalaMepolizumab | 79 | $332,748 |
| Atrovent HfaIpratropium Bromide | 151 | $71,842 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 129 | $65,257 |
| TezspireTezepelumab-Ekko | 15 | $62,738 |
| SymbicortBudesonide/Formoterol Fumarate | 237 | $62,313 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 2,145 | $57,829 |
| Spiriva RespimatTiotropium Bromide | 92 | $53,153 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 65 | $30,390 |
| Ventolin HfaAlbuterol Sulfate | 504 | $27,603 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 141 | $24,209 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $24,067 |
| BreynaBudesonide/Formoterol Fumarate | 132 | $17,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $3,627 | $1,339,5621,576 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Airsupra, Bevespi Aerosphere | $33,377 | $830,1531,302 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,380 | $604,257289 claims |
| MerckDulera | $52 | $4,76114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.